Top-News

Ideaya Bioscience Aktie News

Aktie
WKN:  A2PJPB ISIN:  US45166A1025 US-Symbol:  IDYA Branche:  Biotechnologie Land:  USA
30,60 €
-0,2 €
-0,65%
22:43:42 Uhr
Depot/Watchlist
Marktkapitalisierung *
2,42 Mrd. €
Streubesitz
-
KGV
-8,18
neu: Nachhaltigkeits-Score
22 %
Index-Zuordnung
-

Ideaya Bioscience News

01.12.25 - PR Newswire
IDEAYA Biosciences Announces IND Clearance for IDE034, a Potential First-in-Class Bispecific B7H3/PTK7 TOP1 ADC Targeting Multiple Solid Tumor Types
IDEAYA Biosciences Announces IND Clearance for IDE034, a Potential First-​in-Class Bispecific B7H3/PTK7 TOP1 ADC Targeting Multiple Solid Tumor Types PR Newswire
28.11.25 - PR Newswire
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) PR Newswire
24.11.25 - PR Newswire
IDEAYA Biosciences to Participate in Upcoming December 2025 Investor Relations Events
IDEAYA Biosciences to Participate in Upcoming December 2025 Investor Relations Events PR Newswire
04.11.25 - PR Newswire
IDEAYA Biosciences Reports Third Quarter 2025 Financial Results and Provides Business Update
IDEAYA Biosciences Reports Third Quarter 2025 Financial Results and Provides Business Update PR Newswire
31.10.25 - PR Newswire
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) PR Newswire
27.10.25 - PR Newswire
IDEAYA Biosciences to Participate in Upcoming November 2025 Investor Relations Events
IDEAYA Biosciences to Participate in Upcoming November 2025 Investor Relations Events PR Newswire
20.10.25 - PR Newswire
IDEAYA Biosciences Announces Positive Phase 2 Data for Darovasertib in the Neoadjuvant Setting of Primary Uveal Melanoma in a Proffered Paper Oral Presentation at ESMO 2025
IDEAYA Biosciences Announces Positive Phase 2 Data for Darovasertib in the Neoadjuvant Setting of Primary Uveal Melanoma in a Proffered Paper Oral Presentation at ESMO 2025 ...
20.10.25 - PR Newswire
IDEAYA Biosciences Reports Positive Median Overall Survival Data from Phase 2 Trial of the Darovasertib and Crizotinib Combination in First-line Metastatic Uveal Melanoma at the 2025 Society for Melanoma Research Congress
IDEAYA Biosciences Reports Positive Median Overall Survival Data from Phase 2 Trial of the Darovasertib and Crizotinib Combination in First-​line Metastatic Uveal Melanoma at the ...
15.10.25 - PR Newswire
Next-Generation Targeted Therapies Reshape Precision Oncology Landscape
Next-​Generation Targeted Therapies Reshape Precision Oncology Landscape PR Newswire
15.10.25 - PR Newswire
Next-Generation Targeted Therapies Reshape Precision Oncology Landscape
Next-​Generation Targeted Therapies Reshape Precision Oncology Landscape PR Newswire
26.09.25 - PR Newswire
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) PR Newswire
08.09.25 - PR Newswire
Breakthrough Therapy Designations Surge as $50B Cancer Drug Partnerships Reshape Market
Breakthrough Therapy Designations Surge as $50B Cancer Drug Partnerships Reshape Market PR Newswire
08.09.25 - PR Newswire
Breakthrough Therapy Designations Surge as $50B Cancer Drug Partnerships Reshape Market
Breakthrough Therapy Designations Surge as $50B Cancer Drug Partnerships Reshape Market PR Newswire
08.09.25 - PR Newswire
IDEAYA Biosciences Announces Positive Data From Phase 1/2 Combination Trial of IDE397, a potential first-in-class MAT2A inhibitor, and Trodelvy® in MTAP-Deletion Urothelial Cancer
IDEAYA Biosciences Announces Positive Data From Phase 1/2 Combination Trial of IDE397, a potential first-​in-class MAT2A inhibitor, and Trodelvy® in MTAP-​Deletion Urothelial ...
08.09.25 - PR Newswire
IDEAYA Biosciences Announces Positive Interim Phase 2 Data for Darovasertib in the Neoadjuvant Setting of Primary Uveal Melanoma
IDEAYA Biosciences Announces Positive Interim Phase 2 Data for Darovasertib in the Neoadjuvant Setting of Primary Uveal Melanoma PR Newswire
07.09.25 - PR Newswire
IDEAYA Biosciences and Hengrui Pharma Present Positive Phase 1 Data for IDE849 (SHR-4849), a Potential First-in-Class DLL3 TOP1 ADC, in Small Cell Lung Cancer at the IASLC 2025 World Conference on Lung Cancer
IDEAYA Biosciences and Hengrui Pharma Present Positive Phase 1 Data for IDE849 (SHR-4849), a Potential First-​in-Class DLL3 TOP1 ADC, in Small Cell Lung Cancer at the ...
04.09.25 - PR Newswire
IDEAYA Biosciences Announces First-Patient-In for Phase 1/2 Combination Trial of IDE397, A Potential First-in-Class MAT2A Inhibitor, and Trodelvy® in MTAP-Deletion Non-Small Cell Lung Cancer
IDEAYA Biosciences Announces First-​Patient-In for Phase 1/2 Combination Trial of IDE397, A Potential First-​in-Class MAT2A Inhibitor, and Trodelvy® in MTAP-​Deletion Non-Small ...
03.09.25 - PR Newswire
IDEAYA Biosciences Announces IND Submission for IDE892, a Potential Best-In-Class PRMT5 Inhibitor for MTAP-Deletion Solid Tumors
IDEAYA Biosciences Announces IND Submission for IDE892, a Potential Best-​In-Class PRMT5 Inhibitor for MTAP-​Deletion Solid Tumors PR Newswire
02.09.25 - PR Newswire
Servier and IDEAYA Biosciences Partner to Bring Darovasertib, a Promising Uveal Melanoma Treatment, to Patients Worldwide
Servier and IDEAYA Biosciences Partner to Bring Darovasertib, a Promising Uveal Melanoma Treatment, to Patients Worldwide PR Newswire
29.08.25 - PR Newswire
IDEAYA Biosciences to Present First Median Overall Survival Data from Phase 2 Trial of the Darovasertib / Crizotinib Combination in Metastatic Uveal Melanoma at the 2025 Society for Melanoma Research Congress
IDEAYA Biosciences to Present First Median Overall Survival Data from Phase 2 Trial of the Darovasertib / Crizotinib Combination in Metastatic Uveal Melanoma at the 2025 Society ...

Newssuche

Videos

newspaper
10:20 Uhr +1,73%
Technical Trading: Gold Zukauf Chance
Gold Long Typ: Turbo Open End WKN: VC5S7W Hebel: 2 Laufzeit: OpenEnd Einstieg: Market ... Mehr »